<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Can ALNY&#x27;s Key Partnerships With Pharma Giants Drive Long-Term Growth?</title>
    <meta name="description" content="The drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth, driven by patient demand.; Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo, and Amvuttra — which together generated $1.14 billion in net product revenues, representing a 47% year-over-year increase i; Building on positive phase II KARDIA data, Alnylam and Roche plan to launch the global phase III ZENITH CV outcomes study by late 2025, enrolling about 11,000 high-risk hypertension patients." />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>Can ALNY&#x27;s Key Partnerships With Pharma Giants Drive Long-Term Growth?</h1>
<div class="muted">2025-09-08 14:15:00+00:00</div>
<hr />
<div class="list"><ul>
  <li>The drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth, driven by patient demand.</li><li>Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo, and Amvuttra — which together generated $1.14 billion in net product revenues, representing a 47% year-over-year increase i</li><li>Building on positive phase II KARDIA data, Alnylam and Roche plan to launch the global phase III ZENITH CV outcomes study by late 2025, enrolling about 11,000 high-risk hypertension patients.</li><li>The agreement regarding cemdisiran underwent a modification last year.</li><li>Alnylam, in collaboration with Roche, is developing investigational RNAi therapy zilebesiran in a mid-stage study (KARDIA-3) to treat hypertension.</li><li>The study will test whether twice-yearly 300 mg doses of zilebesiran can reduce the risk of major adverse cardiovascular events compared to placebo.</li><li>Recently, the companies reported encouraging Cohort A results, where a single 300 mg dose of zilebesiran achieved clinically meaningful and sustained reductions in office and ambulatory systolic blood pressure, as well a</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/alnys-key-partnerships-pharma-giants-141500157.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=Can+ALNY%27s+Key+Partnerships+With+Pharma+Giants+Drive+Long-Term+Growth%3F%0A%E2%80%A2+The+drug+generated+%24801.9+million+in+global+sales+in+the+first+half+of+2025%2C+representing+a+staggering+89%25+year-over-year+growth%2C+driven+by+patient+demand.%0A%E2%80%A2+Alnylam+Pharmaceuticals%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fcan-alny-s-key-partnerships-with-pharma-giants-drive-long-term-growth%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>